Market overview
The global injectable drug delivery market is worth USD 19.6 bn in 2026 and is forecast to reach USD 46.4 bn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Prefilled syringes is the largest by device segment.
| Scope | Injectable drug delivery devices: prefilled syringes, autoinjectors, pen injectors, cartridges, needle-free injectors and on-body injectors sold to drug makers and patients. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 18.0 bn |
| Value 2026 | USD 19.6 bn |
| Value 2036 | USD 46.4 bn |
| CAGR 2026-2036 | 9.0% |
| Volume 2026 | 15,184 million units |
| Volume 2036 | 34,197 million units |
| Average price 2026 | USD 1.29 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Injectable Drug Delivery market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 19.6 bn |
| 2027 | USD 21.4 bn |
| 2028 | USD 23.3 bn |
| 2029 | USD 25.4 bn |
| 2030 | USD 27.7 bn |
| 2031 | USD 30.2 bn |
| 2032 | USD 32.9 bn |
| 2033 | USD 35.9 bn |
| 2034 | USD 39.1 bn |
| 2035 | USD 42.6 bn |
| 2036 | USD 46.4 bn |
Injectable Drug Delivery market segmentation
By device
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Prefilled syringes | 38.0% | 32.2% | USD 7.5 bn | 7.2% |
| Pen injectors and cartridges | 24.0% | 21.3% | USD 4.7 bn | 7.7% |
| Autoinjectors | 22.0% | 24.5% | USD 4.3 bn | 10.2% |
| Needle-free injectors | 6.0% | 6.1% | USD 1.2 bn | 9.2% |
| On-body and wearable injectors | 10.0% | 15.9% | USD 2.0 bn | 14.2% |
By therapy
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Diabetes and obesity | 36.0% | 41.2% | USD 7.1 bn | 10.5% |
| Autoimmune and inflammation | 20.0% | 20.0% | USD 3.9 bn | 9.0% |
| Oncology | 14.0% | 14.0% | USD 2.7 bn | 9.0% |
| Vaccines | 16.0% | 11.5% | USD 3.1 bn | 5.5% |
| Other | 14.0% | 13.3% | USD 2.7 bn | 8.5% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 38.0% | 32.0% | USD 7.5 bn | 7.1% |
| Clinics | 22.0% | 20.0% | USD 4.3 bn | 8.0% |
| Home care | 40.0% | 48.0% | USD 7.8 bn | 11.0% |
By container material
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Glass | 52.0% | 42.0% | USD 10.2 bn | 6.7% |
| Polymer | 36.0% | 42.0% | USD 7.1 bn | 10.7% |
| Coated hybrid | 12.0% | 16.0% | USD 2.4 bn | 12.2% |
By administration route
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Subcutaneous | 44.0% | 48.0% | USD 8.6 bn | 9.9% |
| Intramuscular | 24.0% | 22.0% | USD 4.7 bn | 8.1% |
| Intravenous | 28.0% | 26.0% | USD 5.5 bn | 8.2% |
| Intradermal and other | 4.0% | 4.0% | USD 785 mn | 9.0% |
Top 25 countries for injectable drug delivery by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 84.5% of 2026 revenue and the 25 countries below together hold 96.0%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 8.2 bn | 42.0% | USD 19.9 bn | 9.2% |
| 2 | Germany | USD 1.6 bn | 8.0% | USD 3.3 bn | 7.7% |
| 3 | China | USD 1.6 bn | 8.0% | USD 4.7 bn | 11.7% |
| 4 | Japan | USD 1.2 bn | 6.0% | USD 2.3 bn | 6.8% |
| 5 | France | USD 883 mn | 4.5% | USD 1.9 bn | 7.7% |
| 6 | United Kingdom | USD 883 mn | 4.5% | USD 1.9 bn | 7.7% |
| 7 | Italy | USD 589 mn | 3.0% | USD 1.3 bn | 7.9% |
| 8 | India | USD 589 mn | 3.0% | USD 1.8 bn | 11.6% |
| 9 | Canada | USD 589 mn | 3.0% | USD 1.3 bn | 8.6% |
| 10 | Spain | USD 490 mn | 2.5% | USD 1.0 bn | 7.6% |
| 11 | Brazil | USD 222 mn | 1.1% | USD 604 mn | 10.5% |
| 12 | South Korea | USD 222 mn | 1.1% | USD 483 mn | 8.1% |
| 13 | Australia | USD 222 mn | 1.1% | USD 483 mn | 8.1% |
| 14 | Switzerland | USD 190 mn | 1.0% | USD 413 mn | 8.1% |
| 15 | Mexico | USD 159 mn | 0.8% | USD 432 mn | 10.5% |
| 16 | Netherlands | USD 159 mn | 0.8% | USD 348 mn | 8.2% |
| 17 | Turkey | USD 159 mn | 0.8% | USD 432 mn | 10.5% |
| 18 | Ireland | USD 159 mn | 0.8% | USD 348 mn | 8.2% |
| 19 | Russia | USD 128 mn | 0.7% | USD 279 mn | 8.1% |
| 20 | Belgium | USD 128 mn | 0.7% | USD 279 mn | 8.1% |
| 21 | Taiwan | USD 128 mn | 0.7% | USD 279 mn | 8.1% |
| 22 | Saudi Arabia | USD 94 mn | 0.5% | USD 260 mn | 10.7% |
| 23 | Poland | USD 94 mn | 0.5% | USD 209 mn | 8.3% |
| 24 | Sweden | USD 94 mn | 0.5% | USD 209 mn | 8.3% |
| 25 | Denmark | USD 94 mn | 0.5% | USD 209 mn | 8.3% |
| Rest of world | USD 791 mn | 4.0% | USD 1.8 bn | 8.8% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- BD
- Gerresheimer
- SCHOTT Pharma
- Stevanato Group
- West Pharmaceutical Services
- Terumo
- Phillips-Medisize
- Nemera
Group 2: Regional and specialist players
- Ypsomed
- SHL Medical
- Owen Mumford
- Nipro
- Haselmeier
- medmix
- Biocorp
- Aptar Pharma
- Shandong Weigao Group
Group 3: Emerging and niche players
- Credence MedSystems
- PharmaJet
- Bespak
- Enable Injections
- Subcuject
- Injex Pharma
- Windgap Medical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the injectable drug delivery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 9.0% is calculated from the resulting values.
The market is divided by device, by therapy, by end user, by container material, by administration route. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the injectable drug delivery market?
The global injectable drug delivery market is estimated at USD 18.0 bn in 2025 and USD 19.6 bn in 2026.
How fast will the injectable drug delivery market grow?
It is forecast to reach USD 46.4 bn by 2036, a compound annual growth rate of 9.0% from 2026, an increase of USD 26.8 bn.
Which country is the largest market for injectable drug delivery?
United States is the largest market by revenue at USD 8.2 bn in 2026, 42.0% of the global total. The three largest countries together hold 58.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 11.7% a year from 2026 to 2036.
Which injectable drug delivery segment is largest?
In the by device split, Prefilled syringes is the largest segment with 38.0% of 2026 revenue.
Who are the leading injectable drug delivery companies?
Global leaders include BD, Gerresheimer, SCHOTT Pharma, Stevanato Group.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Pharmaceutical GlassUSD 19.4 bn · 7.2% CAGR
- Medical BillingUSD 20.0 bn · 11.0% CAGR
- NanomedicineUSD 20.1 bn · 9.0% CAGR
- Nasal Drug DeliveryUSD 19.1 bn · 6.2% CAGR
- SyringeUSD 21.2 bn · 6.5% CAGR
- Metered Dose InhalerUSD 17.9 bn · 5.0% CAGR
- Pharmaceutical Cold ChainUSD 21.6 bn · 8.0% CAGR
- Biopharmaceutical LogisticsUSD 21.7 bn · 9.0% CAGR